Feedback

Gut microbiota mediated hypoglycemic effect of Astragalus membranaceus polysaccharides in db/db mice

Affiliation
School of Pharmacy, The Chinese University of Hong Kong, Hong Kong ,Hong Kong SAR ,China
Song, Qianbo;
Affiliation
Institute of Chinese Medicine ,The Chinese University of Hong Kong, Hong Kong ,Hong Kong SAR ,China
Cheng, Sau Wan;
Affiliation
School of Pharmacy, The Chinese University of Hong Kong, Hong Kong ,Hong Kong SAR ,China
Li, Dan;
Affiliation
School of Life Sciences ,The Chinese University of Hong Kong, Hong Kong ,Hong Kong SAR ,China
Cheng, Huiyuan;
Affiliation
School of Pharmacy, The Chinese University of Hong Kong, Hong Kong ,Hong Kong SAR ,China
Lai, Yuen Sze;
Affiliation
School of Life Sciences ,The Chinese University of Hong Kong, Hong Kong ,Hong Kong SAR ,China
Han, Quanbin;
Affiliation
School of Chinese Medicine ,Hong Kong Baptist University, Hong Kong ,Hong Kong SAR ,China
Wu, Hoi Yan;
Affiliation
School of Chinese Medicine ,Hong Kong Baptist University, Hong Kong ,Hong Kong SAR ,China
Shaw, Pang Chui;
Affiliation
School of Pharmacy, The Chinese University of Hong Kong, Hong Kong ,Hong Kong SAR ,China
Zuo, Zhong

Gut microbiota has been reported to be closely associated with Type-II diabetes. Restoration of disordered gut microbiota ecosystem has been developed into a therapeutic strategy and gradually applied on Type-II diabetes treatment with both western drugs and herbal polysaccharides. Although Astragalus membranaceus polysaccharides (AMP) have also been used to treat Type-II diabetes, no study investigated correlations between gut microbiota regulation and its hypoglycemic effect. In the present study, the role of gut microbiota on the hypoglycemic effect of AMP in db/db mice was investigated for the first time. Sixteen days treatment of AMP at the dosage of 600 mg/kg in db/db mice not only alleviated its diabetic symptoms significantly but also restored its gut microbiota community with increased production of fecal short chain fatty acids (SCFA). Our further Pearson correlation analyses revealed that the relative abundance of two intestinal bacteria, Akkermansia and Faecalibaculum , were significantly positively correlated with the hypoglycemic effect of AMP as well as fecal SCFA production. It was also noted that treatment of AMP resulted in increased secretion of glucagon-like peptide-1 (GLP-1) in serum and enhanced intestinal integrity. Further mechanistic study revealed that the increased SCFA after AMP treatment could stimulate GLP-1 secretion and improve intestinal integrity via enhancing the expression of G protein-coupled receptors 41/43 and tight junction proteins (Occudin and ZO-1), respectively, leading to the alleviation of diabetic symptoms in db/db mice.

Cite

Citation style:
Could not load citation form.

Access Statistic

Total:
Downloads:
Abtractviews:
Last 12 Month:
Downloads:
Abtractviews:

Rights

License Holder: Copyright © 2022 Song, Cheng, Li, Cheng, Lai, Han, Wu, Shaw and Zuo.

Use and reproduction: